EdgeMarket › What Affinity Asset Advisors, Llc reported owning
What Affinity Asset Advisors, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.9BPositions
105Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. | 108.2M | 5.6% | 1.3M | 134.75 | +274.1% |
| XENE Xenon Pharmaceuticals Inc. | 97.4M | 5.0% | 1.7M | 60.77 | +61.5% |
| ERAS Erasca, Inc. | 86.6M | 4.5% | 5.3M | 17.63 | +1107.5% |
| INSM INSMED Inc | 78.5M | 4.1% | 480.0K | 125.77 | -2.8% |
| ROIV Roivant Sciences Ltd. | 77.6M | 4.0% | 2.8M | 36.30 | +209.7% |
| SYRE Spyre Therapeutics, Inc. | 64.5M | 3.3% | 1.3M | 106.49 | +551.3% |
| unmapped CUSIP 152309100 | 55.6M | 2.9% | 1.4M | — | — |
| PRAX Praxis Precision Medicines, Inc. | 54.8M | 2.8% | 170.0K | 375.94 | +730.8% |
| ANAB ANAPTYSBIO, INC | 52.1M | 2.7% | 940.0K | 57.74 | +186.6% |
| ALKS Alkermes plc. | 47.7M | 2.5% | 1.4M | 48.33 | +66.8% |
| CYTK CYTOKINETICS INC | 46.2M | 2.4% | 700.5K | 76.84 | +105.9% |
| ABVX Abivax S.A. | 45.1M | 2.3% | 405.0K | 114.95 | +59.9% |
| TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD | 42.2M | 2.2% | 1.4M | 37.34 | +112.0% |
| unmapped CUSIP 03940C100 | 41.7M | 2.2% | 362.8K | — | — |
| unmapped CUSIP 670703107 | 30.7M | 1.6% | 300.0K | — | — |
| unmapped CUSIP 880881107 | 29.7M | 1.5% | 562.6K | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 29.4M | 1.5% | 350.0K | 111.10 | +374.4% |
| LXEO Lexeo Therapeutics, Inc. | 29.0M | 1.5% | 5.1M | 4.88 | +1.7% |
| COGT Cogent Biosciences, Inc. | 28.9M | 1.5% | 750.0K | 36.73 | +209.6% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 28.8M | 1.5% | 55.0K | 516.74 | +31.9% |
| STRO SUTRO BIOPHARMA, INC. | 26.6M | 1.4% | 1.1M | 21.04 | +143.4% |
| FBRX Forte Biosciences, Inc. | 26.2M | 1.4% | 1.0M | 76.92 | +554.1% |
| ORKA Oruka Therapeutics, Inc. | 24.5M | 1.3% | 499.7K | 107.96 | +649.7% |
| TRVI Trevi Therapeutics, Inc. | 23.9M | 1.2% | 2.0M | 17.96 | +142.0% |
| OVID Ovid Therapeutics Inc. | 23.6M | 1.2% | 10.6M | 2.80 | +194.7% |
| ELVN Enliven Therapeutics, Inc. | 23.0M | 1.2% | 586.9K | 59.82 | +204.3% |
| ASND Ascendis Pharma A/S | 21.7M | 1.1% | 95.0K | 253.29 | +31.4% |
| MLYS Mineralys Therapeutics, Inc. | 20.3M | 1.0% | 750.0K | 25.65 | +65.7% |
| AVTX Avalo Therapeutics, Inc. | 20.0M | 1.0% | 1.3M | 19.83 | +115.1% |
| PTGX Protagonist Therapeutics, Inc | 18.1M | 0.9% | 172.1K | 154.32 | +174.4% |
| CLDX Celldex Therapeutics, Inc. | 15.9M | 0.8% | 500.0K | 40.38 | +93.3% |
| ZURA Zura Bio Ltd | 15.3M | 0.8% | 2.6M | 5.85 | +234.3% |
| NRIX Nurix Therapeutics, Inc. | 15.0M | 0.8% | 967.6K | 26.72 | +180.4% |
| SVRA Savara Inc | 13.7M | 0.7% | 2.5M | 5.59 | +80.9% |
| unmapped CUSIP 682143AK8 | 13.2M | 0.7% | 6.5M | — | — |
| CATX Perspective Therapeutics, Inc. | 13.2M | 0.7% | 3.2M | 3.30 | -2.4% |
| HLXC Helix Acquisition Corp. III | 12.7M | 0.7% | 1.2M | 10.93 | — |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 12.5M | 0.6% | 200.0K | 87.11 | +331.2% |
| DMRA Damora Therapeutics, Inc. | 11.7M | 0.6% | 450.0K | 30.82 | +811.9% |
| EPRX EUPRAXIA PHARMACEUTICALS INC. | 11.5M | 0.6% | 1.6M | 6.73 | +27.1% |
| ANRO Alto Neuroscience, Inc. | 11.2M | 0.6% | 500.0K | 34.28 | +899.4% |
| BBIO BridgeBio Pharma, Inc. | 11.1M | 0.6% | 150.0K | 81.50 | +66.7% |
| CGEM Cullinan Therapeutics, Inc. | 11.1M | 0.6% | 781.3K | 21.68 | +190.2% |
| BLTE BELITE BIO, INC | 10.4M | 0.5% | 65.0K | 161.06 | +154.0% |
| WVE Wave Life Sciences, Inc. | 10.2M | 0.5% | 1.4M | 5.29 | -44.0% |
| VERA Vera Therapeutics, Inc. | 10.1M | 0.5% | 250.0K | 32.27 | +46.0% |
| TYRA Tyra Biosciences, Inc. | 9.9M | 0.5% | 257.5K | 26.05 | +154.4% |
| RVMD Revolution Medicines, Inc. | 9.7M | 0.5% | 100.0K | 209.46 | +479.3% |
| JBIO Jade Biosciences, Inc. | 9.0M | 0.5% | 640.0K | 21.34 | +211.5% |
| TVTX Travere Therapeutics, Inc. | 8.9M | 0.5% | 300.0K | 65.71 | +265.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →